AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
Innoplexus Announces New North American Affiliate Helmed by Former Merck KGaA Executive
Leader in Pharmaceutical Research AI expands North American Presence.
HOBOKEN, NJ, May 10, 2018 /24-7PressRelease/ — Innoplexus, a leader in artificial intelligence and data analytics solutions for pharmaceutical and life science research, announced today the opening of Innoplexus Americas. This new affiliate will focus on empowering pharmaceutical companies in the United States and Latin America to achieve new heights of creativity and innovation through augmented data analytics capabilities.
Innoplexus has hired experienced pharmaceutical executive Lawrence Ganti to serve as Innoplexus America’s inaugural CEO. Mr. Ganti comes to Innoplexus with a plethora of leadership experience in the pharmaceutical space. Most recently, he was President of Merck KGaA’s Latin American business. His prior experience includes General Manager roles with Merck in Brasil and India. He was also Head of Commercial Development for Merck’s Emerging Markets Business Unit, where he consolidated the strategy and business analytics functions. Prior to his roles with Merck, Mr. Ganti held positions with McKinsey & Company and various technology starts-ups.
Mr. Ganti’s experience as a global pharmaceutical leader gives him an insider’s perspective on the opportunities and challenges within pharmaceutical innovation. He stated, “Data analytics has become a core competency for Pharma. It’s definitely not something you want to outsource. What brought me to Innoplexus is our approach of empowering pharma with customized ecosystems enhanced with relevant data grounded in the life sciences. Our tools and people speak the language of pharma and apply that to our AI and Machine Learning technologies.”
Featured News
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience.Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
Parexel and Innoplexus Unveil Single Source of COVID-19 Information for
COVID-19 Clearinghouse enables direct access to latest COVID-19 datasets, publications, research and clinical trialsBOSTON and DURHAM, N.C. and ESCHBORN, Germany,…
New app for cancer patients
Das Eschborner Unternehmen Innoplexus hat eine neue App namens „Curia“ für Krebspatienten veröffentlicht. Mit dem Computerprogramm, das sich unentgeltlich herunterladen…
Innoplexus wins Silver Edison Award for OntosightⓇ Explore
Frankfurt, Germany, March 26, 2020 — Innoplexus AG has been honored with the Silver Edison Award 2020 for its proprietary…
AI CTP engine estimated failure for Biogen’s aducanumab
While drug development can be incredibly lucrative, it is a very risky business. German company Innoplexus has developed a domain-specific…
How can AI be leveraged for Clinical Trial Prediction?
Successful clinical trials occur at a ratio of 1 in 10, costing around $2-$3 billion, with drugs taking 10–12 years…
Innoplexus launches new Blockchain platform for Pharma innovation
If your loved one was diagnosed with a potentially fatal illness, wouldn’t you want all the information possible to be…